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Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquired
endocrine resistance in patients with ER-positive metastatic breast cancer (MBC). Functional studies
revealed that these ESR1 mutations lead to constitutive activity of the ER, meaning that the receptor is
active in absence of its ligand estrogen, conferring resistance against several endocrine agents. While
recent clinical studies reported that the occurrence of ESR1 mutations is rare in primary breast cancer
tumors, these mutations are more frequently observed in metastatic tissue and circulating cell-free
DNA of MBC patients pretreated with endocrine therapy. Given the assumed impact that the presence
of ESR1 mutations has on outcome to endocrine therapy, assessing ESR1 mutations in MBC patients is
likely to be of significant interest to further individualize treatment for MBC patients. Here, ESR1 muta-
tion detection methods and the most relevant pre-clinical and clinical studies on ESR1 mutations regard-
ing endocrine resistance are reviewed, with particular interest in the ultimate goal of guiding treatment
decision-making based on ESR1 mutations.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Endocrine therapy with selective estrogen receptor modula-
tors/downregulators (SERMs/SERDs) or by estrogen deprivation
using aromatase inhibitors (AIs), is the most important treatment
modality for estrogen receptor (ER)-positive metastatic breast can-
cer (MBC) patients [1]. Unfortunately, 40% of patients do not ben-
efit from first-line endocrine therapy due to intrinsic resistance,
and the remainder of patients initially responding will eventually
develop resistance during therapy [1]. Several mechanisms have
been linked to endocrine resistance, however, no marker for resis-
tance has reached wide clinical use yet [2–4]. Recently, mutations
in the gene encoding ERa, ESR1, have attracted particular interest
as a mechanism for endocrine resistance in MBC. Large-scale
next-generation sequencing (NGS) efforts on MBC tissues revealed
that these mutations are enriched in MBC patients treated with
endocrine agents while these variants are not or only at very low
frequencies present in primary tumor tissue [5,6]. Importantly, this
implies that their presence has to be assessed in metastatic lesions,
or in ‘‘liquid biopsies” such as circulating cell-free DNA (cfDNA) asa representative of metastatic tumor cells. Here we review the pros
and cons of current detection methods for ESR1mutations, the pre-
clinical and clinical studies investigating ESR1mutations and high-
light its potential role in treatment decision-making in MBC
patients.Functional studies on ESR1 mutations
The ER belongs to the nuclear hormone receptor superfamily [7]
and consists of two activation function (AF)-1/2 domains, DNA
binding and hinge domains, and a ligand binding domain (LBD)
(Fig. 1). The ER functions as a ligand-dependent transcription fac-
tor. Binding of estradiol to the LBD leads to a conformational
change of helix 12, resulting in recruitment of coregulatory pro-
teins [8]. This eventually yields transcription of genes important
in normal physiological processes but also for breast tumorigenesis
and breast cancer (BC) progression [9].
Recent NGS efforts revealed that somatic ESR1 mutations in the
LBD were more frequently present in metastatic lesions than pre-
viously thought. In preclinical models to evaluate the role of
ESR1 mutations in endocrine resistance, it was demonstrated that
cell lines transfected with a D538G, Y537S, L536Q, Y537N,
Y537C, S463P or E380Q ESR1mutation exert activity in the absence
of estrogen [6,10–15] (Fig. 1). This constitutive activity suggests
that estrogen-depriving therapies such as AIs are not or less effec-
Fig. 1. Schematic overview of the different domains of the ER. Activation function
(AF) domain-1 present at the N-terminus acts in a ligand-independent manner,
whereas, the AF-2 within the ligand binding domain (LBD) is dependent on
estradiol for its activation [52]. The DNA binding domain encodes two zinc finger
molecules, playing an important role in receptor dimerization and binding of the ER
to specific DNA sequences: the estrogen response element (ERE) [53]. H = hinge
region. ESR1mutations, some hotspot mutations shown as vertical red lines, mainly
occur in the C-terminal domain of the receptor encoding for the LBD of the ER.
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fected with mutant ESR1 variants were however still responsive
to treatment with tamoxifen and fulvestrant, though sensitivity
to these drugs was relatively impaired compared to ESR1 wildtype
transfected cell lines [5,6,12,13]. Similar observations were
recently made for novel SERM/SERD hybrid endocrine therapies
pipendoxifene and bazedoxifene [16].Fig. 2. Various techniques for ESR1mutation detection. The pyramid represents the
range in which the genome is investigated. ESR1 mutations can be detected by
large-scale NGS efforts such as whole-genome sequencing or whole-exome
sequencing, or by more targeted methods as targeted sequencing of the ESR1 gene
only, or by the interrogation of individual mutations in ESR1 by digital PCR.Techniques to detect ESR1 mutations
Several techniques can be used to assess ESR1 mutations in tis-
sue or cfDNA (Fig. 2), all having their own advantages and disad-
vantages. Importantly, these techniques widely vary in their
sensitivity. NGS can be performed either in the context of whole
genome sequencing, as part of a whole exome panel, or as part of
a targeted ESR1 panel. While NGS is an established and widely used
approach for mutation detection in tumor tissue, mutation detec-
tion in cfDNA is more challenging, as the relative number of
mutant to wildtype DNA alleles has to be taken into account. Fre-
quencies of circulating tumor DNA (ctDNA) vary largely between
patients, frequently being below 1% of the total cfDNA [17], which
is beyond the sensitivity of conventional NGS. Therefore, tech-
niques based on digital PCR (dPCR) have been introduced enabling
the detection of ctDNA in frequencies as low as 0.001% [18,19]. In
dPCR-based techniques, each individual DNA molecule, within its
own partition, is able to react with a specific probe for wildtype
ESR1 and another probe for a specific ESR1 mutant. There are sev-
eral commercially available dPCR-based assays (e.g. digital PCR,
droplet digital PCR (ddPCR), BEAMing), differing in used reagents
and sample readouts, but generally having similar sensitivity
[17,20]. In a study comparing conventional targeted NGS with
dPCR to detect mutations in cfDNA, threefold more D538G ESR1
mutations in cfDNA were observed using dPCR than with NGS
[21]. One disadvantage of dPCR assays is however that only a sub-
set of hotspot mutations can be evaluated. Other assays, using
some sort of target-enrichment prior to analysis, can be used to
detect multiple hotspot mutations (OnTarget assay [22,23]) or
multiple frequently mutated genes (e.g. SafeSeqS [24], CAPP-Seq
[25]), however to date these assays have not yet been reported
to be used to detect ESR1 mutations.Clinical studies on the significance of ESR1 mutations
ESR1 mutations in primary and metastatic tumor tissue
Although already described anecdotally in the the ’90s
[11,26,27], ESR1 mutations were thought to be rare in BC. They
occur only in up to 3% of primary tumors using NGS (Supplemen-
tary Table 1) [5,6,12,13]. Using more sensitive dPCR-based tech-
niques, the ESR1 mutation rate in primary BC tumors may mildly
increase [28,29], however, only at very low variant allele frequen-
cies (VAF; 0.07–0.2%) [29].
In contrast to mutation rates in primary BC, the landmark
papers of Toy et al. [6] and Robinson et al. [13] showed much
higher ESR1 mutation rates in metastatic lesions (Supplementary
Table 2). Toy and colleagues [6] found ESR1 mutations (predomi-
nantly D538G and Y537S) in metastatic tissues in 9/36 ER-
positive MBC patients who had received at least 3 months of endo-
crine therapy. All patients with an ESR1 mutation were at least
treated with two lines of endocrine therapy; all containing an AI.
In an independent cohort of 44 metastatic tumors from patients
pretreated with endocrine therapy, 5 metastases (11%) harbored
an ESR1 mutation.
Likewise, Robinson et al. [13] demonstrated ESR1 mutations in
6/11 (55%) evaluated metastatic biopsies of ER-positive MBC
patients. All patients with an ESR1 mutation were pretreated with
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tumors of patients with a metastatic ESR1 mutation harbored an
ESR1mutation. Based on these findings and the accompanied func-
tional studies, both groups hypothesized that ESR1mutations are a
common mechanism underlying endocrine resistance, developing
during estrogen deprivation, especially in the context of AI
treatment.
Prompted by these findings, several studies investigated ESR1
mutations in metastatic tissue of MBC patients. In 5/13 (38%) ER-
positive MBC patients, who failed on multiple lines of endocrine
treatment, a D538G ESR1 mutation was reported [12]. Further-
more, Jeselsohn et al. [5] detected in 9/76 (12%) ER-positive meta-
static tumors ESR1 mutations (Y537N/C/S and D538G) using NGS,
whereas none of the 115 ER-negative tumors they assessed had
such mutations. In both studies no ESR1mutations in matched pri-
mary tumors were detected [5,12].
In a study using dPCR, an ESR1 mutation was revealed in meta-
static tissue of 11/55 ER-positive MBC patients [28]. Notably, poly-
clonal ESR1 mutations (multiple ESR1 mutations in one sample)
were observed in 4/11 (36%) patients. Also of particular interest
was that two patients with ESR1 mutations were not pretreated
with any therapies at all and 4/11 only received prior treatment
with tamoxifen, supporting a previous observation [5] that ESR1
mutations are not exclusively found following AI treatment. In
another study [29] applying dPCR, ESR1 mutations were found in
3/43 primary tumors, 1/12 bone metastasis tissues and 3/38 brain
metastasis tissues in ER-positive MBC patients. The prevalence of
ESR1 mutations and their VAF were higher in bone (1.4% VAF)
and especially in brain metastases (34.3–44.9% VAF) compared to
primary tumors (0.07–0.2% VAF), suggesting an enrichment of
ESR1-mutant subclones in metastatic tissue.
All these tissue-based studies provided important insights into
the prevalence of ESR1 mutations and the population of patients in
which they occur. However, the biggest disadvantage of these
studies is that they concerned mostly small, heterogeneously trea-
ted, and retrospectively selected patient cohorts. Furthermore, of
note is that biopsies were usually taken at various time points
and therefore the evidence at which moment ESR1 mutations
emerge, which is suggested to be mainly after AI treatment, is indi-
rect. The majority of the above mentioned drawbacks are mainly
driven by the fact that taking metastatic biopsies is a cumbersome
procedure and even impossible in some patients, not easily allow-
ing the assessment of ESR1mutations over time. In addition, taking
metastatic biopsies may lead to sample bias due to tumor hetero-
geneity [30]. Therefore, recent studies have focused on ESR1 muta-
tion detection in ‘‘liquid biopsies” as a patient-friendly alternative
to taking biopsies from metastatic lesions.
ESR1 mutations in ‘liquid biopsies’
Circulating blood biomarkers such as circulating tumor cells
(CTCs) and cfDNA are increasingly used as non-invasive surrogate
‘‘liquid biopsies”, and are thought to represent the most important
metastatic tumor sites [31,32]. Both these types of liquid biopsies
can be measured in peripheral blood, with CTCs being intact tumor
cells and cfDNA being DNA mainly derived from apoptotic tumor
cells. Recently, several studies investigating the presence of ESR1
mutations in liquid biopsies, particularly in cfDNA, have been pub-
lished (Table 1).
To evaluate NGS and dPCR techniques to detect ESR1 mutations
in plasma, Guttery et al. examined cfDNA of 48 ER-positive MBC
patients [21]. In 3/48 patients (6%), they observed an ESR1 muta-
tion in cfDNA using NGS. In one patient with a D538G mutation
also CTCs, isolated by the CellSearch system, were sequenced,
and the same mutation was detected in CTCs. When dPCR was per-
formed in the same cohort for the D538G mutation only, theD538G mutation was found in 6 additional patients (15%) at VAF
below 1%, underlining the limited sensitivity of NGS to detect
low frequent mutations. In eleven patients, serial plasma samples
were available. Interestingly, in one patient an ESR1 mutation
was present at baseline and was further enriched (0.4% VAF to
13.6% 3 months later) while treated with chemotherapy (doc-
etaxel/vinorelbine).
To further explore whether ESR1 mutations present in metas-
tases are also represented in the cfDNA, Chu et al. [33] assessed
ESR1 mutations in plasma cfDNA in 11 ER-positive MBC patients
in whom the ESR1 mutation status in a metastatic lesion was
assessed by NGS. All ESR1 mutations (8/8) observed in the meta-
static lesions were also observed in the cfDNA using dPCR. In one
patient with an ESR1 wildtype metastatic lesion, a low frequency
ESR1 mutation was observed in the cfDNA. It should however be
noted that the cfDNA was obtained two months after the biopsy,
meaning that changes in ESR1 mutation status could also be due
to therapy-related effects emerging after the initial biopsy. In an
independent cohort consisting of 8 ER-positive patients, dPCR
was once more demonstrated to be able to detect ESR1 mutations
in cfDNA, and in two more patients an ESR1mutation was observed
in the cfDNA but not in the metastatic lesion. This study further
underscored that dPCR is able to readily detect ESR1 mutations in
the cfDNA and that cfDNA seems to represent ESR1 mutations in
the metastatic lesions. Also, strikingly, ESR1 mutations were
detected in cfDNA but not in metastatic lesions, which may be
indicative of heterogeneity within the metastatic lesion or between
multiple metastases.
Another study only used dPCR to detect ESR1 mutations [29],
and ESR1 mutations were detected in 7/29 MBC patients (24%),
with one patient having polyclonal ESR1 mutations. All patients
with an ESR1 mutation in cfDNA received at least one line of endo-
crine treatment, mainly AIs or tamoxifen. In this series, also an
ESR1 mutation was seen in a patient who had only received prior
treatment with fulvestrant. Of particular interest were the serial
blood draws in the patient with the polyclonal ESR1 mutations,
which revealed that two mutations were enriched during AI treat-
ment and chemotherapy, while one mutation was absent after
treatment. This may suggest that different mutations react differ-
ently to different treatments.
Schiavon and colleagues [34] were the first to present a study in
which ESR1 mutations were assessed in a relatively large cohort of
MBC patients. With dPCR to examine cfDNA from MBC patients at
the time of progression under endocrine therapy, ESR1 mutations
were observed in 18/128 patients (14%), with D538G mutations
comprising 56% of all observed ESR1 mutations. Polyclonality of
ESR1 mutations was observed in 21% of the patients. All patients
in whom ESR1 mutations were observed had received prior AI
treatment, while no ESR1 mutations were observed in a subset of
22 patients who had only received tamoxifen treatment. Interest-
ingly, ESR1 mutations were mainly detected in patients who
received AIs only in the metastatic setting (36%), and not in
patients who received AIs only in the adjuvant setting (4%) or in
the adjuvant and metastatic setting (8%). In accordance were
observations in two relatively small independent cohorts, in which
no ESR1mutations were observed in 32 BC biopsies taken at recur-
rence after adjuvant AI treatment or in 7 cfDNA samples of MBC
patients who received adjuvant AI treatment only. Regarding the
outcome of patients with ESR1 mutations, subgroup analyses in
ESR1 mutant versus wildtype patients revealed a significantly
poorer progression-free survival (PFS) on subsequent AI treatment
in patients harboring an ESR1 mutation, although these analyses
should be seen as exploratory given the small number of patients
eligible for such analyses.
The observations by Schiavon et al. suggest that AI treatment in
the metastatic setting, but not in adjuvant setting, causes ESR1
Table 1
Overview of ESR1 mutation analysis in ‘‘liquid biopsies” of metastatic breast cancer patients.
Patients Method ESR1 mutation Substrate Number of patients
with ESR1 mutations
D538G Y537S Y537N Y537C Other Refs.
6 pts with ER-positive MBC either off or
progressing on therapy
RNA
sequencing
whole transcriptome Cultured
CTCs
3/6 (50%) 1/6
(17%)
1/6
(17%)
– – 1/6 (17%) L536P [43]
48 pts with ER-positive MBC receiving endocrine
therapy
NGS E380Q, V392I, P535H, Y537C/N/S,
D538G
cfDNA 3/48 (6%) 1/48
(2%)
1/48
(2%)
– – 1/48 (2%) E380Q [21]
48 pts with ER-positive MBC receiving endocrine
therapy
ddPCR D538G cfDNA 9/48 (19%) 9/48
(19%)
NP NP NP NP
3 pts with ESR1mutation detected in cfDNA by
NGS
NGS E380Q, V392I, P535H, Y537C/N/S,
D538G
CTCs 1/3 (33%) 1/3
(33%)
– – – –
128 pts with ER-positive MBC, progression on
therapy
ddPCR D538G, Y537C/N/S, L536R cfDNA 18/128 (14%) 14/128
(11%)
3/128
(2%)
4/128
(3%)
2/128
(2%)
2/128 (2%) L536R [34]
11 pts with ER-positive MBC (8 with known ESR1
mutation in metastatic biopsy by NGS)
ddPCR D538G, Y537N/S cfDNA 9/11 (82%) 6/11
(55%)
3/11
(27%)
1/11
(9%)
NP NP [33]
8 pts with ER-positive MBC ddPCR D538G, Y537N/S cfDNA 6/8 (75%) 4/8
(50%)
2/8
(25%)
1/8
(13%)
NP NP
29 pts with MBC ddPCR K303R, S463P, Y537C/N/S, D538G cfDNA 7/29 (24%) 6/29
(21%)
2/29
(7%)
– 1/29
(3%)
– [29]
161 pts ER-positive MBC with prior sensitivity to
nonsteroidal AI (SoFEA)
ddPCR E380Q, L536R, Y537C/N/S, D538G,
S463P
cfDNA 63/161 (39%) 29/161
(18%)
16/161
(10%)
23/161
(14%)
3/161
(2%)
6/161 (4%) E380Q, 6/161 (4%)
S463P, 2/161(1%) L536R
[38]
360 pts with ER-positive MBC with progression on
endocrine therapy (PALOMA3)
ddPCR E380Q, L536R, Y537C/N/S, D538G,
S463P
cfDNA 91/360 (25%) 51/360
(14%)
23/360
(6%)
14/360
(4%)
5/360
(1%)
22/360 (6%) E380Q, 4/360 (1%)
S463P, 1/360 (1%) L536R
153 pts with ER-positive MBC pre-treated with AI
(FERGI)
BEAMing E380Q, S463P, V524E, P535H,
L536H/P/Q/R, Y537C/N/S, D538G
cfDNA 57/153 (37%) 31/153
(20%)
19/153
(12%)
10/143
(7%)
6/143
(4%)
15/153 (26%) E380Q, 5/143 (3%)
S463P, 7/143 (5%) L536P
[36]
5 pts with MBC (4 ER+, 1 TN), with P100 CTCs NGS ESR1 exome 40 single
CTCs
10/40 (25%) 7/40
(18%)
– – – 3/40 (8%) E380Q [44]
5 pts with MBC (4 ER+, 1 TN), with P100 CTCs NGS ESR1 exome cfDNA 3/5 (60%) 2/5
(40%)
– – 1/5
(20%)
1/5 (20%) E380Q
541 pts with ER-positive MBC with progression
after nonsteroidal AI (BOLERO-2)
ddPCR D538G, Y537S cfDNA 156/541 (29%) 113/
541
(21%)
72/541
(13%)
– – – [40]
ddPCR = droplet digital PCR, NP = Not performed. Number of patients with a ESR1 mutation in different study cohorts are listed. The specific mutations observed in these patients are also shown; in case of polyclonality, these
numbers may exceed the total number of patients with a ESR1 mutation.
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L. Angus et al. / Cancer Treatment Reviews 52 (2017) 33–40 37mutations. This may suggest selection of subclones already present
in the primary tumor, or in the metastases when the tumor load is
increased and the probability of acquiring mutations increases
[35]. This first observation could be in line with the previously
mentioned findings by Wang et al. whom found ESR1 mutations
at extremely low VAF in primary tumors of MBC patients with
ESR1 mutations. While the study by Schiavon and colleagues also
provided evidence for an impaired response to AI treatment, larger
studies were needed to confirm these findings and to examine
whether MBC patients with ESR1 mutations will have improved
responses on alternative therapies.ESR1 mutations and outcome on endocrine therapies
In the randomized phase II FERGI trial, baseline plasma samples
of patients failing to AI treatment randomized either to fulvestrant
combined with the pan-PI3K inhibitor pictilisib or to the combina-
tion of fulvestrant and placebo, were examined for ESR1 and
PIK3CA mutations in tissue and cfDNA using BEAMing [36]. They
detected ESR1 mutations in cfDNA in 57/153 (37%) of patients at
baseline; 13 patients (23%) harbored polyclonal mutations. Sur-
prisingly, the prevalence of the E380Q mutation was rather high
(26%), while this mutation was previously not often observed. No
ESR1 mutations were detected in 42 matched primary tumors of
patients with ESR1 mutations in cfDNA. PIK3CA mutations were
observed in the cfDNA of 40% of the patients and were generally
concordant with findings in matched metastatic tissue. For the
ESR1 mutations, discordances between the cfDNA and metastatic
biopsies occurred more frequently and cfDNA sometimes harbored
more ESR1 mutations than the metastatic biopsies. These analyses
were however limited by the fact that metastatic tissue and cfDNA
were generally not collected on the same day. Of note was that the
median VAF of PIK3CA mutations was markedly higher than for
ESR1 mutations (3.6% versus 0.45%). The higher VAFs and concor-
dance with tissue probably reflect that PIK3CA mutations usually
occur in earlier stages of BC [37], in contrast to ESR1 mutations.
Similar to Wang and colleagues [29], it was observed in multiple
longitudinal samples in patients with polyclonal ESR1 mutations
that different ESR1 mutations reacted differently under treatment.
The clinical analyses in the fulvestrant/placebo arm of the FERGI
study revealed that patients with an ESR1 mutation in ctDNA had
no impaired PFS on fulvestrant compared to ESR1 wildtype. When
the analyses were further restricted to those patients with poly-
clonal ESR1 mutations or ESR1 mutation with VAF above the med-
ian, also no effect on PFS was observed. Also no differences in PFS
were observed in patients with and without ESR1 mutations
receiving fulvestrant and pictilisib.
The data from the FERGI study suggested that fulvestrant does
not have reduced activity in patients with ESR1 mutations. How-
ever, data on the impact of ESR1 mutations on outcome to fulves-
trant versus AI treatment and the addition of other agents to
fulvestrant treatment were still missing. These gaps were filled
by data from two phase III randomized trials, reported by Fribbens
et al. whom assessed ESR1mutations in cfDNA by dPCR [38]. In the
SoFEA study, patients who had previously benefited from a non-
steroidal AI were randomly assigned to fulvestrant combined with
anastrozole, fulvestrant with placebo, or exemestane alone. Muta-
tions were detected at baseline in 63/161 (39%) patients; 27/55
(49%) patients evaluable for polyclonal mutations had such muta-
tions. Patients with an ESR1 mutation had an improved PFS after
taking a fulvestrant-containing regimen versus exemestane (med-
ian PFS fulvestrant-containing 5.7 versus exemestane 2.6 months,
P = 0.02), in contrast to ESR1 wildtype patients in whom a similar
PFS was found (5.4 months versus 8.0 months, P = 0.77). Within
the exemestane-treated patients, patients with ESR1 mutations(n = 18) had a worse PFS compared to patients having an ESR1
wildtype (n = 39), (median PFS 2.6 versus 8.0 months P = 0.01).
In the PALOMA3 study, patients who failed on prior endocrine
therapy were randomized to fulvestrant in combination with the
CDK4/6-inhibitor palbociclib or to fulvestrant and placebo. In
91/360 patients (25%), ESR1 mutations were detected with poly-
clonal mutations observed in 26/91 (29%). The main study revealed
a significant PFS benefit in patients receiving fulvestrant/palboci-
clib versus patients receiving fulvestrant alone (median 9.5 versus
4.6 months, P = 0.0001) [39]. This PFS benefit was maintained in
patients with ESR1 mutations (median 9.4 versus 3.6 months,
P = 0.002), while no PFS difference was observed between ESR1
mutants and wildtype in patients treated with fulvestrant/palboci-
clib (median 9.4 versus 9.5 months, respectively). Although
median PFS seemed to be slightly worse in the ESR1 mutated
patients treated with fulvestrant alone (3.6 months 95% CI,
2.0–5.5) compared to ESR1 wildtype (5.4 months 95% CI 3.5–7.4),
this was not statistically significant, which is in line with the
results of the FERGI study [36].
So far, the only large study providing overall survival (OS) data
with respect to ESR1 mutations is the phase III BOLERO-2 study
[40]. In this study, postmenopausal women who progressed on
an AI were randomized to the AI exemestane combined with ever-
olimus, or exemestane and placebo. Overall, 156/541 (29%) of
evaluable patients had either a D583G and/or Y537S ESR1mutation
detected in their cfDNA, with double-mutations detected in 30/541
(6%) patients. ESR1mutations were more prevalent in patients who
had previously received AI treatment for metastatic disease (33%)
than in patients who had received AIs as adjuvant therapy (11%),
supporting previous data from Schiavon et al. [34]. The results of
the main study revealed that median PFS was significantly
improved in patients treated with everolimus and exemestane
compared to exemestane and placebo (7.8 months versus
3.2 months), though the combination therapy did not result in
improved OS [41,42]. In the ESR1 mutation-driven subgroup anal-
yses for PFS in the exemestane arm, patients with a mutation in
D538G had a shorter PFS than ESR1 wildtype patients (2.7 versus
3.9 months), which is in accordance with the findings of the SoFEA
study [40,38]. When the analysis was restricted to patients with a
Y537S mutation only, this association was not observed, which
may be related to the limited sample size for these subgroup anal-
yses. Of note is that the PFS of ESR1 wildtype patients was
3.9 months in this study, while in the SoFEA study this was
8 months. This discrepancy in PFS might be due to differences in
selection criteria of both studies. In the SoFEA trial only patients
who received a non-steroidal AI as adjuvant therapy or as first-
line therapy for MBC were included whereas patients in the
BOLERO-2 trial were also included after receiving more lines of
therapy for MBC representing a more advanced disease stage.
When everolimus was added to exemestane this resulted in an
improved median PFS in both D538G mutated (5.8 months; HR
0.34, 95% CI 0.02–0.6) and wildtype patients (8.5 months; HR 0.4,
95% CI 0.3–0.5), suggesting that ESR1 mutated patients could still
benefit from the addition of everolimus. Of note is that benefit of
the addition of everolimus was not demonstrated for patients with
a Y537S mutation alone (4.2 months; HR 0.98, 95% CI 0.5–1.9), or
with both a Y537S and D538G mutation (5.4 months; HR 0.53,
95% CI 0.2–1.3). Again, one should keep in mind that these analyses
may have suffered from the limited sample size of patients with
only a Y537S mutation or a polyclonal ESR1 mutation. If larger
future studies confirm that patients with a Y537S indeed do not
benefit from the addition of everolimus, this mutation might be
used to select for patients who should be treated with other treat-
ment modalities. Overall, the absolute median PFS interval seemed
to be shorter in patients with an ESR1 mutation than in ESR1
wildtype patients, however, no formal analyses on these potential
38 L. Angus et al. / Cancer Treatment Reviews 52 (2017) 33–40differences were observed. In this context, it was intriguing that OS
analyses according to ESR1 mutation status showed that patients
with an ESR1 mutation had a worse OS compared to wildtype
patients (median OS 22 versus 32 months). Noteworthy, the type
of individual mutations was also suggested to influence OS, with
a median OS of 26 months for patients with a D538Gmutation only
and 20 months for the Y537S mutation alone. In patients harboring
both mutations the OS was even worse with a median OS of
15 months. Overall, these results may indicate that ESR1mutations
are associated with more aggressive disease biology.Discussion
The putative role of ESR1 mutations in endocrine resistance has
sparked a wide interest in techniques enabling their detection, the
conditions under which they appear, and whether their detection
can ultimately assist treatment decision-making in MBC patients.
Regarding the best substrate for ESR1 mutation detection, data
frommultiple studies suggests that the cfDNA compartment some-
times provides additional mutations compared to matched meta-
static tumor material. This may indicate that cfDNA is more
representative of the whole somatic tumor landscape. Another
obvious advantage of cfDNA over metastatic biopsies is that it
can easily be obtained repeatedly during treatment. Therefore,
future studies on the clinical relevance of ESR1 mutations should
preferably be performed using cfDNA, measuring mutations not
only at baseline but also sequentially during treatment. Of note,
ESR1 mutations can also be detected in CTCs [21,43,44], but at this
point it is unclear how ESR1 mutation detection in CTCs relates to
ESR1 mutation detection in cfDNA, and if this adds anything to
ESR1 mutation analyses in cfDNA.
Assessing ESR1mutations in tissue and cfDNA provided clues as
to how these ESR1 mutations are enriched in MBC patients. Very
strong indirect evidence exists for the enrichment of these ESR1
mutations during treatment with AIs in the metastatic setting.
However, to date no direct evidence for the enrichment of ESR1
mutations under AI treatment has been presented yet. In this con-
text it is also of note that several studies observed ESR1 mutations
in metastases or cfDNA from patients treated with SERMs or SERDs
only, or from patients not treated with endocrine therapy at all
[5,21,28,29]. This further underlines that the understanding on
how ESR1 mutations exactly occur is still limited. ESR1 mutations
are present at very low frequencies in primary BC tumors using
dPCR [29], supporting the hypothesis that ESR1 mutations may
already be subclonally present in the primary tumor, and because
of growth advantages, become the more prominent clone under
treatment pressure [34]. ESR1 mutations might also occur as a
result of mutational processes such as initiated by the APOBEC
enzymes, however the mutational pattern of the hotspot ESR1
mutations (T > A/C/G) does not follow an APOBEC pattern or the
pattern of any other mutational signature known to date [45,46].
While the exact mechanism behind the enrichment of ESR1
mutations in MBC is still unknown, the clinical relevance of ESR1
mutations being present in cfDNA becomes evident. PFS after treat-
ment with the AI exemestane was impaired in the patients harbor-
ing an ESR1mutation [38,40], while fulvestrant had similar efficacy
in patients with an ESR1 mutation versus patients without an ESR1
mutation. Given these results with fulvestrant, efficacy of tamox-
ifen may also be unaffected in patients harboring ESR1 mutations,
however, no clinical data on this is present as of yet. For the addi-
tion of other agents to endocrine treatment, for example palboci-
clib or everolimus, the question remains whether the presence of
ESR1 mutations is of any predictive significance for the efficacy of
these agents. While the ESR1 mutation status did not seem to
impact median PFS in patients receiving fulvestrant and palboci-clib, the presence of an ESR1 mutation in patients treated with
exemestane and everolimus might be associated with decreased
PFS compared to ESR1 wildtype patients.
Since a raise in ESR1 mutation ratio during the course of treat-
ment may be indicative of progressive disease [47] and ESR1muta-
tions in general are associated with poor outcome [40], it will be of
particular interest to see whether certain treatments (for example
fulvestrant combined with palbociclib or specific chemotherapeu-
tic regimen) are able to select against ESR1 mutant subclones.
Recently, it was shown that upon the discontinuation of anti-
epidermal growth factor receptor (EGFR) antibodies, resistant
KRAS mutant clones decay, allowing re-challenges with anti-
EGFR antibodies in particular patients [48]. If ESR1 mutations are
lost with certain treatment regimen, this could potentially allow
re-challenges with AIs in a subset of patients.
Also currently unknown is whether the different ESR1 muta-
tions result in distinctive phenotypes. Functional studies on ESR1
mutations did not specifically focus on differences between various
ESR1mutations, and for some ESR1mutations that have been mea-
sured in clinical studies (e.g. K303R, V524E, P535H, L536H/P/R),
very little functional evaluation of its constitutive activity and
potential role in endocrine resistance has been performed at all.
In addition, clinical studies to date have generally been underpow-
ered for subgroup analyses evaluating differential effects of differ-
ent ESR1mutations. Even further complicating such analyses is the
described polyclonality of ESR1 mutations. Multiple studies with
anecdotal longitudinal sampling data suggested that in patients
with polyclonal ESR1 mutations there are differential effects of
therapy on different ESR1mutations. This suggests that ESR1muta-
tions are present in different subclones, and not in the same cell.
Theoretically, this may mean that patients with polyclonal muta-
tions are more difficult to treat given the wider repertoire of resis-
tance mutations. However, in rather small analyzed groups of
patients with polyclonal ESR1 mutations treated with fulvestrant
such effects were not observed. Given that some ESR1 mutations
are rarer than others, the most pragmatic way to evaluate the prog-
nostic value of these rare ESR1 mutations will likely be in the form
of a meta-analysis in due time, as it is virtually impossible to eval-
uate the prognostic value of these mutations in single studies. In
addition, functional studies evaluating all LBD ESR1 mutations
described in patients to date, validating their constitutive activity
and exploring potential differential effects of different ESR1 muta-
tions are of interest.
The current evidence on ESR1 mutations warrants prospective
studies in which patients are randomized and treated according
to the ESR1 mutation status in cfDNA. Therefore, standardized
methods to process plasma, to isolate cfDNA and to prepare and
analyze the dPCR chips are needed. A lot of the recent ESR1 muta-
tion research was performed on cfDNA samples that were subopti-
mally collected. For example, in the SoFEA trial, plasma was
collected in EDTA tubes and processed up to 9 days after sample
collection which may have consequences for the sensitivity to
detect ESR1 mutations, especially in the context of longitudinal
sampling [49,50]. Recently, it was demonstrated that blood col-
lected in CellSave or BCT blood tubes assures optimal quality of
cfDNA for dPCR or NGS analyses for up to 96 hours after the blood
draw [49–51], providing opportunities to send blood samples to
remote locations for plasma isolation. In addition, it is of utmost
importance to assess variables such as intra-assay, inter-assay,
inter-lab and inter-observer variability when using dPCR, which
are currently not only poorly studied for ESR1 mutations, but also
for cfDNA analyses in general.
In conclusion, the presence of ESR1 mutations in patients with
ER-positive MBC has high potential for clinical validity and utility.
Prospective studies in which the exact role of how ESR1 mutations
can be used to guide treatment decision-making have to be initi-
L. Angus et al. / Cancer Treatment Reviews 52 (2017) 33–40 39ated, but firstly standardization of protocols to assess these muta-
tions will be necessary to eventually allow clinical
implementation.
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